BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc.
August 01 2014 - 9:38AM
Business Wire
Shareholder rights law firm Johnson & Weaver, LLP has
commenced an investigation into whether certain officers and
directors of Biota Pharmaceuticals, Inc, (Nasdaq: BOTA) violated
state or federal laws. Biota Pharmaceuticals, Inc., a
biopharmaceutical company, focuses on the discovery and development
of anti-infective products.
On August 1, 2014 Biota announced its experimental influenza
drug failed to meet the main goal in a mid-stage study. In April
2014 the U.S. Department of Health and Human Services pulled out of
a contract to support the drug's development. The contract provided
up to $231 million in financial support for the development of
laninamivir octanoate for the treatment of influenza A and B in the
United States.
If you have information that could assist in this
investigation, including former employees and others, or if you are
a Biota shareholder and are interested in learning more about the
investigation or your legal rights and remedies, please contact Jim
Baker (jimb@johnsonandweaver.com) by email or by
phone at 619-814-4471.
About Johnson & Weaver,
LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder
rights law firm with offices in California, New York and Georgia.
The firm represents individual and institutional investors in
shareholder derivative and securities class action lawsuits. For
more information about the firm and its attorneys, please visit
http://www.johnsonandweaver.com. Attorney advertising. Past results
do not guarantee future outcomes.
Johnson & Weaver, LLPJim Baker,
619-814-4471jimb@johnsonandweaver.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024